Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA’s New Criminal Investigations Chief Wants Global Reach

This article was originally published in The Tan Sheet

Executive Summary

Office of Criminal Investigations Director George Karavetsos talks about the Park Doctrine and off-label enforcement in an interview.


Related Content

US FDA’s OCI Director Is Leaving For Private Practice
FDA's Beleaguered Criminal Investigations Unit Now Facing Congressional Scrutiny
FDA Reprint Policy Expands To Clinical Practice Guidelines, Medical Reference Texts
FDA Investigators Search For Silver Bullets In Off-Label Probes
FDA Counterfeit Screening Tool Gets Field Test In Ghana; Corning Prepares Device For Mass Production
Rick Blumberg, FDA’s “Fearless And Passionate” Chief Litigation Counsel, Dies At 69
Amgen Off-label Settlement Includes Exec Oversight Of Individual Product Compliance
Pharma Under The Gun: FDA And DoJ Use Tough Tactics In Investigations
Abbott’s Depakote Off-Label Settlement With DoJ Includes Court Probation
FDA Envisions International Focus Groups Navigating Globalization Issues


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts